JP6382187B2 - インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 - Google Patents

インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 Download PDF

Info

Publication number
JP6382187B2
JP6382187B2 JP2015518599A JP2015518599A JP6382187B2 JP 6382187 B2 JP6382187 B2 JP 6382187B2 JP 2015518599 A JP2015518599 A JP 2015518599A JP 2015518599 A JP2015518599 A JP 2015518599A JP 6382187 B2 JP6382187 B2 JP 6382187B2
Authority
JP
Japan
Prior art keywords
indirubin
composition
less
nanoparticulate
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015518599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520241A (ja
JP2015520241A5 (enExample
Inventor
ウー，ビン
Original Assignee
フォスフォレックス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォスフォレックス，インコーポレーテッド filed Critical フォスフォレックス，インコーポレーテッド
Publication of JP2015520241A publication Critical patent/JP2015520241A/ja
Publication of JP2015520241A5 publication Critical patent/JP2015520241A5/ja
Application granted granted Critical
Publication of JP6382187B2 publication Critical patent/JP6382187B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015518599A 2012-06-21 2013-06-21 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 Expired - Fee Related JP6382187B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662469P 2012-06-21 2012-06-21
US61/662,469 2012-06-21
PCT/US2013/046981 WO2013192493A1 (en) 2012-06-21 2013-06-21 Nanoparticles of indirubin, derivatives thereof and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018144837A Division JP2018199685A (ja) 2012-06-21 2018-08-01 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法

Publications (3)

Publication Number Publication Date
JP2015520241A JP2015520241A (ja) 2015-07-16
JP2015520241A5 JP2015520241A5 (enExample) 2016-08-12
JP6382187B2 true JP6382187B2 (ja) 2018-08-29

Family

ID=49769412

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015518599A Expired - Fee Related JP6382187B2 (ja) 2012-06-21 2013-06-21 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2018144837A Pending JP2018199685A (ja) 2012-06-21 2018-08-01 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2020001832A Pending JP2020073564A (ja) 2012-06-21 2020-01-09 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2021118361A Pending JP2021181447A (ja) 2012-06-21 2021-07-19 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2023021518A Pending JP2023062070A (ja) 2012-06-21 2023-02-15 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018144837A Pending JP2018199685A (ja) 2012-06-21 2018-08-01 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2020001832A Pending JP2020073564A (ja) 2012-06-21 2020-01-09 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2021118361A Pending JP2021181447A (ja) 2012-06-21 2021-07-19 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2023021518A Pending JP2023062070A (ja) 2012-06-21 2023-02-15 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法

Country Status (6)

Country Link
US (3) US10039829B2 (enExample)
EP (2) EP3597178A1 (enExample)
JP (5) JP6382187B2 (enExample)
CN (2) CN104602675B (enExample)
CA (1) CA2914782C (enExample)
WO (1) WO2013192493A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6382187B2 (ja) * 2012-06-21 2018-08-29 フォスフォレックス，インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス，インコーポレーテッド インジルビン固体分散体組成物
RU2630561C2 (ru) * 2015-10-20 2017-09-11 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Способ получения водно-солевых дисперсий фуллерена
CN115969814A (zh) * 2017-03-29 2023-04-18 法斯瑞斯公司 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法
RU2721318C1 (ru) * 2019-02-28 2020-05-18 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ получения золей и суспензий
WO2020227151A1 (en) * 2019-05-03 2020-11-12 Azora Therapeutics, Inc. Compositions comprising indigo and/or an indigo derivative and methods of use thereof
CN114668744A (zh) * 2022-03-23 2022-06-28 成都大学 一种靛玉红固体脂质纳米粒及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929242A (en) * 1986-11-26 1990-05-29 Baxter International Inc. Solution and method for maintaining patency of a catheter
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
ATE484514T1 (de) * 2001-12-13 2010-10-15 Natrogen Therapeutics Inc Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
MXPA05009757A (es) * 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
CN1615852A (zh) * 2003-11-10 2005-05-18 许军 靛玉红口服滴丸及制备工艺
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
KR20080003322A (ko) * 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 도세탁셀 및 이의 유사체의 나노입자 배합물
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
MX2007011772A (es) * 2005-03-23 2007-12-05 Elan Pharma Int Ltd Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas.
US7825087B2 (en) * 2005-04-12 2010-11-02 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
US8158582B2 (en) * 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
CN101023944A (zh) * 2006-02-23 2007-08-29 黎明涛 靛玉红衍生物在制备治疗神经退行性变疾病药物中的应用
CN101074229B (zh) * 2007-06-08 2010-09-01 无锡杰西医药科技有限公司 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US20090274621A1 (en) * 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier
EP2113253B1 (en) 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
CN101362066B (zh) * 2008-09-27 2010-12-22 同济大学 脂质体包埋量子点的二氧化硅微球的制备方法及其产品
CN101775082B (zh) * 2010-02-09 2012-06-27 中国药科大学 基于两性离子的电荷反转型壳聚糖衍生物及其在药剂中的应用
CN102018736B (zh) * 2010-11-19 2012-03-28 成都中医药大学 一种青黛饮片及其制备方法
CN102228433B (zh) * 2011-06-29 2012-11-28 上海中医药大学 过饱和自微乳制剂及其制备方法和应用
JP6382187B2 (ja) * 2012-06-21 2018-08-29 フォスフォレックス，インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法

Also Published As

Publication number Publication date
EP2863897A1 (en) 2015-04-29
US20190054174A1 (en) 2019-02-21
CA2914782C (en) 2021-05-25
US10675350B2 (en) 2020-06-09
EP3597178A1 (en) 2020-01-22
JP2018199685A (ja) 2018-12-20
CN104602675A (zh) 2015-05-06
JP2021181447A (ja) 2021-11-25
US20220168423A1 (en) 2022-06-02
CA2914782A1 (en) 2013-12-27
CN104602675B (zh) 2019-06-28
JP2015520241A (ja) 2015-07-16
CN110123763A (zh) 2019-08-16
EP2863897B1 (en) 2019-06-19
EP2863897A4 (en) 2016-01-27
JP2023062070A (ja) 2023-05-02
US20150110878A1 (en) 2015-04-23
WO2013192493A1 (en) 2013-12-27
US10039829B2 (en) 2018-08-07
JP2020073564A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
JP4611641B2 (ja) Ｍａｐキナーゼ阻害剤のナノ粒子組成物
JP4842514B2 (ja) 血管新生抑制剤のナノ粒子組成物
JP4838514B2 (ja) 低粘度液体剤形
EP1658053B1 (en) Novel compositions of sildenafil free base
JP2018199685A (ja) インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
US20040105889A1 (en) Low viscosity liquid dosage forms
JP2013136621A (ja) ナノ粒子アリピプラゾール製剤
JP2006516646A (ja) フルチカゾン製剤
BRPI0613540A2 (pt) formulações de imatinib mesilato nanoparticuladas
JP2009543797A (ja) ナノ粒子ソラフェニブ製剤
KR20080017065A (ko) 나노입자형 아세트아미노펜 제제
JP2009518300A (ja) モメタゾン組成物ならびにその作製方法および使用方法
US20110159054A1 (en) Nanoparticulate bicalutamide formulations
JP2011514360A (ja) 血管新生阻害剤のナノ粒子組成物
JP4865990B2 (ja) ナノ粒子メゲストロール製剤
CA2654909A1 (en) Nanoparticulate kinase inhibitor formulations
EP1898882B1 (en) Nanoparticulate ebastine formulations
JP2008543862A (ja) ナノ粒子アゼルニジピン製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180801

R150 Certificate of patent or registration of utility model

Ref document number: 6382187

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees